Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 426-439

  Peterziel, Heike ^a   Müller, Julia ^a   Danner, Andreas ^b   Barbus, Sebastian ^b   Liu, Hai Kun ^c   Radlwimmer, Bernhard ^b   Pietsch, Torsten ^d   Lichter, Peter ^b   Schütz, Günther ^c   Hess, Jochen ^a,c,e   Angel, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b DKFZ   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

glioma; Jun; podoplanin; promoter methylation; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PODOPLANIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN TISSUE; BRAIN TUMOR; CONTROLLED STUDY; DOWN REGULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; METHYLATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUBVENTRICULAR ZONE; TRANSCRIPTION REGULATION;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84859534661     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos055     Document Type: Article

References (57)

1. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2235-2241.
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807-1812.
3. Argyriou AA, Kalofonos HP. Molecularly targeted therapies for malignant gliomas. Mol Med. 2009;15(3-4):115-122.
4. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010;12(1):49-57.
5. Toedt G, Barbus S, Wolter M, et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer. 2011;128(5): 1095-1103.
6. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3): 157-173. (Pubitemid 43357943)
7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
8. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166-193.
9. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
10. Matsui K, Breiteneder-Geleff S, Kerjaschki D. Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol. 1998;9(11):2013-2026. (Pubitemid 28482149)
11. Rishi AK, Joyce-Brady M, Fisher J, et al. Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol. 1995;167(1): 294-306.
12. Zimmer G, Klenk HD, Herrler G. Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line. J Biol Chem. 1995;270(30):17815- 17822.
13. Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog. 1997;20(1):10-18. (Pubitemid 27461534)
14. Scholl FG, Gamallo C, Vilaro S, Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci. 1999;112(Pt 24):4601-4613. (Pubitemid 30034809)
15. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1a as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003;278(51):51599-51605. (Pubitemid 38020404)
16. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154(2):385-394. (Pubitemid 29094089)
17. Baluk P, McDonald DM. Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann N Y Acad Sci. 2008;1131:1-12. (Pubitemid 351758499)
18. Makinen T, Norrmen C, Petrova TV. Molecular mechanisms of lymphatic vascular development. Cell Mol Life Sci. 2007;64(15):1915-1929. (Pubitemid 47094431)
19. Schacht V, Ramirez MI, Hong YK, et al. T1a/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003;22(14):3546-3556. (Pubitemid 36898332)
20. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008;28(5B):2997-3006.
21. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007;96(1):1-5. (Pubitemid 46094630)
22. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumorrelevant genes associated with survival. Clin Cancer Res. 2009;15(21):6541-6550.
23. Durchdewald M, Angel P, Hess J. The transcription factor Fos: a Janus-type regulator in health and disease. Histol Histopathol. 2009;24(11):1451-1461.
24. DurchdewaldM,Guinea-Viniegra J,Haag D, et al. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 2008;68(17):6877-6883.
25. Hummerich L, Muller R, Hess J, et al. Identification of novel tumourassociated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25(1):111-121. (Pubitemid 43050009)
26. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
27. Liu HK, Belz T, Bock D, et al. The nuclear receptor tailless is required for neurogenesis in the adult subventricular zone. Genes Dev. 2008;22(18):2473-2478.
28. Angel P, Allegretto EA, Okino ST, et al. Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature. 1988;332(6160):166- 171. (Pubitemid 18083563)
29. Offringa R, Gebel S, van Dam H, et al. A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell. 1990;62(3): 527-538.
30. Hagmeyer BM, Kö nig H, Herr I, et al. Adenovirus E1A negatively and positively modulates transcription of AP-1 dependent genes by dimerspecific regulation of the DNA binding and transactivation activities of Jun. EMBO J. 1993;12(9):3559-3572. (Pubitemid 23256443)
31. Smeal T, Angel P, Meek J, Karin M. Different requirements for formation of Jun: Jun and Jun: Fos complexes. Genes Dev. 1989;3(12B):2091-2100. (Pubitemid 20023234)
32. Stein B, Baldwin AS, Jr, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-kB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 1993;12(10):3879-3891. (Pubitemid 23282764)
33. Ryffel GU, Kugler W, Wagner U, Kaling M. Liver cell specific gene transcription in vitro: the promoter elements HP1 and TATA box are necessary and sufficient to generate a liver-specific promoter. Nucleic Acids Res. 1989;17(3):939-953. (Pubitemid 19062882)
34. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene. 1996;13(5):1065-1072. (Pubitemid 26329093)
35. van den Boom J, Wolter M, Kuick R, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcriptionpolymerase chain reaction. Am J Pathol. 2003;163(3):1033-1043. (Pubitemid 37040139)
36. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
37. Peterziel H, Sackmann T, Strelau J, et al. F-spondin regulates neuronal survival through activation of disabled-1 in the chicken ciliary ganglion. Mol Cell Neurosci. 2011;46(2):483-497.
38. Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007;67(17):8198-8206. (Pubitemid 47395156)
39. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65(6):529-539. (Pubitemid 44288937)
40. Abounader R, Ranganathan S, Kim BY, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem. 2001;76(5):1497-1508. (Pubitemid 32198254)
41. Koul D, Shen R, Shishodia S, et al. PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway. Mol Cell Biochem. 2007;300(1-2):77-87. (Pubitemid 46881818)
42. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 2008;27(41):5416-5430.
43. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008;7(9):1321-1325.
44. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3):469-479. (Pubitemid 29316287)
45. Kolenda J, Jensen SS, Aaberg-Jessen C, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol. 2011;103(1):43-58.
46. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007;447(7143):433-440. (Pubitemid 46816750)
47. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev. 2006;20(23): 3215-3231.
48. Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4(11): e7752.
49. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep. 2011;11(3):291-297.
50. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342-352.
51. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17(4):362-375.
52. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008;373(1): 36-41.
53. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
54. Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med. 2010;31(2):135-144.
55. Waldner MJ, Neurath MF. The molecular therapy of colorectal cancer. Mol Aspects Med. 2010;31(2):171-178.
56. Lechner M, Boshoff C, Beck S. Cancer epigenome. Adv Genet. 2010;70:247-276.
57. Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327-340.